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Background: Rural Australians have poorer survival for most common cancers, due partially to later diagnosis. Internationally, several initiatives to
improve cancer outcomes have focused on earlier presentation to healthcare and timely diagnosis. We aimed to measure the effect of community-
based symptom awareness and general practice-based educational interventions on the time to diagnosis in rural patients presenting with breast,
prostate, colorectal or lung cancer in Western Australia.
Methods: 2 2 factorial cluster randomised controlled trial. Community Intervention: cancer symptom awareness campaign tailored for rural
Australians. GP intervention: resource card with symptom risk assessment charts and local cancer referral pathways implemented through multiple
academic detailing visits. Trial Area A received the community symptom awareness and Trial Area B acted as the community campaign control region.
Within both Trial Areas general practices were randomised to the GP intervention or control. Primary outcome: total diagnostic interval (TDI).
Results: 1358 people with incident breast, prostate, colorectal or lung cancer were recruited. There were no significant differences in the median or
ln mean TDI at either intervention level (community intervention vs control: median TDI 107.5 vs 92 days; ln mean difference 0.08 95% CI  0.06–
0.23 P¼ 0.27; GP intervention vs control: median TDI 97 vs 96.5 days; ln mean difference 0.004 95% CI  0.18–0.19 P¼ 0.99). There were no
significant differences in the TDI when analysed by factorial design, tumour group or sub-intervals of the TDI.
Conclusions: This is the largest trial to test the effect of community campaign or GP interventions on timeliness of cancer diagnosis. We found no
effect of either intervention. This may reflect limited dose of the interventions, or the limited duration of follow-up. Alternatively, these
interventions do not have a measurable effect on time to cancer diagnosis.
Rural Australians are more likely to die within 5 years of a cancer
diagnosis than people from metropolitan areas (Underhill et al,
2006, Coory et al, 2013). While overall survival for most common
cancers in Australia is improving, the rural–urban differential has
been widening, with significant excess deaths due to lung,
colorectal, breast and prostate cancer in regional Australia
(AIHW, 2010). Similar disparities in cancer outcomes between
rural and urban populations have been described internationally
(Singh et al, 2011, Meilleur et al, 2013). As part of the International
Cancer Benchmarking Partnership, a major focus on under-
standing variations in cancer outcomes has been later presentation
to healthcare and later diagnosis (Butler et al, 2013)
Previous studies have shown that patients living in rural
Australia are less likely to receive curative or reconstructive
surgery, radiotherapy or anti-cancer drug treatment (.Coory and
Baade, 2005, Hall et al, 2005, Mitchell et al, 2006, Baade et al,
2011b) Policy initiatives have focused, therefore, on reducing
disparities in access to treatment (Department of Health and
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Ageing, 2010) but, while this is an important determinant of
outcome, later presentation and stage at diagnosis have also been
observed in cancer patients from rural compared with those from
urban areas (Jong et al, 2005, Baade et al, 2011a). International
research suggests that the time taken to appraise symptoms and
seek help (the ‘patient interval’), management in primary care and
access to diagnostic procedures are also key determinants of cancer
outcomes (Allgar and Neal, 2005). Prolonged time to diagnosis is
associated with poorer survival from several common cancers
(Neal et al, 2015). Our previous exploratory mixed-methods
research identified characteristics of rural Australians including
optimism, stoicism and machismo which affected decisions to seek
medical help (Emery et al, 2013a). Over-optimism towards health
meant some participants were more likely to find alternative
benign explanations for their symptoms. Optimism was associated
with stoic responses to symptoms which meant that severe and
continuous symptoms were self-managed. Related to such stoicism
in men, was the need to be perceived as tough or macho and less
willing to seek help. Many participants discussed these character-
istics of optimism, stoicism and machismo as core features of what
being ‘rural’ in Australia meant. These features, as well as poorer
access to health care, contributed to later presentation of cancer
(Emery et al, 2013a). In addition, there were significant overall
differences between cancers in terms of time from presentation in
general practice (GP) to referral, from GP referral to specialist
appointment, and from specialist appointment to cancer diagnosis.
These differences were due to the nature of presenting symptoms,
limited access to diagnostic tests and a requirement for multiple
visits to specialists (Emery et al, 2013b). However, there are no
published studies which have compared symptom awareness, help
seeking or diagnostic intervals between rural and urban people
with cancer or in general community samples.
One of the approaches to reducing later presentation to
healthcare has been community symptom awareness campaigns.
These formed a major component of the UK National Awareness
and Early Diagnosis Initiative as part of the policy to improve
cancer outcomes (.Cancer Research UK, 2010) A systematic review
of cancer symptom awareness campaigns published in 2009
found insufficient evidence to determine their effectiveness on
presentation to healthcare (Austoker et al, 2009). Since then
further studies examining the impact of the English ‘Be Clear on
Cancer’ campaigns have begun to show potential effects on
presentation and cancer diagnoses but these have all relied on
before-and-after observational designs (Athey et al, 2011).
There have been no trials in Australia of the efficacy of cancer
symptom awareness campaigns, and relatively few studies
examining community symptom awareness. The International
Cancer Benchmarking Partnership compared symptom awareness
and barriers to consultation between nations, including Australia,
but did not compare rural and urban populations(Forbes et al,
2013).
A second approach has aimed at improving recognition of
patients presenting to primary care whose symptoms may warrant
early investigation for cancer. Until recently, there was little
epidemiological evidence demonstrating how well symptoms
predict risk of an underlying cancer from primary care populations
(Emery et al, 2013a). Analysis of data in case-control studies using
large UK general practice databases, notably the CAPER (CAncer
Prediction in ExeteR) studies (Hamilton et al, 2005a,b, 2006,
Hamilton, 2009) and QCancer research (Hippisley-Cox and
Coupland, 2013a,b), has led to significant advances in our
understanding of the epidemiology of cancer symptoms in primary
care. The CAPER studies quantified the risk of individual and
paired symptoms, signs and primary care investigations for a
number of cancers including colorectal, lung and prostate. These
have been applied to create risk assessment tools (RATs) in paper
versions (Hamilton et al, 2013) and are currently undergoing
evaluation as computerised decision support tools embedded in the
electronic medical records of general practices(Moore et al, 2016).
Various interventions including audit and feedback, educational
visits, guidelines and decision support have been tested in general
practice to improve cancer diagnosis, but none of the 22 trials
included in a systematic review of interventions to support cancer
diagnosis in primary care examined effects on diagnostic delay
(Mansell et al, 2011a).
The findings from our exploratory research in rural Western
Australia (WA) (Emery et al, 2013a) (Emery et al, 2013b)
contributed to the development of the interventions and design
of the improving rural cancer outcomes (IRCO) Trial: a factorial
cluster-randomised controlled trial of community-based and
general practice-based interventions which aimed to measure the
effect of these interventions on the time to diagnosis in rural
patients presenting with prostate, breast, colorectal or lung cancer
in WA.
MATERIALS AND METHODS
As the protocol for the IRCO trial has been published (http://
bmjopen.bmj.com/content/4/9/e006156), (Emery et al, 2014) here
we report the methods in brief. (Australian New Zealand Clinical
Trial Registry ACTRN12610000872033).
Study design. This was a factorial cluster randomised controlled
trial conducted in Western Australia with communities and
general practices allocated to the interventions. Two Trial Areas
were matched for population size, demographics including age and
Aboriginality, and similar cancer incidence, based on the most
recent available data when the trial was planned. Trial Area A
comprised the Wheatbelt (155 256 km2; Australian Standard
Geographical Classification RA3 (outer regional) and RA4
(remote)), Goldfields (770 488 km2; RA3, RA4 and RA5 (very
remote)) and Great Southern (39 007 km2; RA3 and RA4) regions
total population in 2010:140 554), and Trial Area B included the
Peel/South West (29 646 km2;RA2 (inner regional) and RA3) and
MidWest (470 000 km2; RA3, RA4 and RA5) regions (total
population in 2010:233 063) (WA Country Health Service, 2011).
In these areas, populations are widely distributed across many
small and medium sized towns; smaller communities are served by
general practices often based at least 50–100 kms away. Peel and
the South West each have one large regional city (Mandurah and
Bunbury respectively).
Primary ethics approval was obtained from The University of
Western Australia’s Human Research Ethics Committee (RA/4/1/
4527).
Randomisation and masking. Trial Area A was randomly
allocated to receive the community symptom awareness campaign
intervention and Trial Area B acted as the community campaign
control region (Community level randomisation). Within Trial
Area A (Community Intervention) and Trial Area B (Community
Control) general practices were randomised to receive the
education intervention or control, stratified by practice size
(General Practice level randomisation). GPs who worked at more
than one practice were identified, and these practices were treated
as a single cluster for the purpose of randomisation to avoid
contamination. We used a cluster version of Zelen’s method of
post-randomised consent: intervention practices were invited to
receive the educational intervention while control practices
received no information about the trial (Adamson et al, 2006).
This enabled non-intervention practices to act as true controls by
minimising the Hawthorne effect in a situation where placebo and
double-blind experimental conditions are impossible to achieve.
Furthermore, it allowed a pragmatic delivery of the intervention
and measure of its uptake in routine practice. Intervention
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practices which declined the invitation to receive the educational
intervention were analysed on an intention-to-treat basis (i.e.,
patients from these practices were included in the GP Intervention
group). Randomisation was performed by the trial statistician
(MB). A database containing all practices categorised by workforce
size was created and then random samples of practices were
selected stratified for size of practice using ‘samplepps’ The
research staff who collected outcome data and the trial statistician
were blinded to group allocation.
Participants. While the whole community and general practices
within the communities were the targets of the interventions,
outcome measurement was at the level of the individual patient.
From 1 March 2012, 4 months after the interventions commenced,
all patients meeting the following criteria were invited to contribute
their data for the trial:
 adults aged over 18 years;
 diagnosed with breast, lung, colorectal or prostate cancer
between 1 January 2012 and the recruitment end date of 31
March 2014; and
 resident of Campaign Intervention or Campaign Control regions
at the time of cancer diagnosis.
Eligible participants were identified via:
1. The WA Cancer Registry (WACR), a population-based registry
with mandatory notification since 1981. A letter and participant
information sheet was mailed on behalf of the WACR directly
to newly diagnosed cancer patients. After 3 weeks non-
responders were followed up by the research team via phone
or mail.
2. The Cancer Council Western Australia’s residential lodges,
where a large proportion of rural cancer patients stayed during
their treatment in metropolitan cancer centres. Lodge staff gave
eligible patients a participant information sheet, followed up by
contact from the research team.
Participants signed a consent form with agreement to access
their medical records, and completed the SYMPTOM question-
naire. Participants were not specifically informed of the trial
hypotheses; while those from Trial Area A may have been aware of
the symptom awareness campaign, they did not know that the data
they provided were used to measure the impact of the campaign.
Procedures. Both interventions were delivered from 1 November
2011 to 31 December 2013. The Community Intervention: the Find
Cancer Early campaign The symptom awareness campaign
materials were developed from the Cancer Research UK ‘Spot
Cancer Early’ and the UK National Health Service ‘3-week cough’
campaigns. They were significantly modified to incorporate the
findings of our previous exploratory research, including a focus on
specific barriers to help-seeking such as stoicism and machismo,
and to make them relevant to the rural Australian community
following feedback from several community forums. (Emery et al,
2013a,b) (Supplementary Materials for examples). Some of the
campaign materials were explicitly targeted at individuals aged
over 40 (e.g. the symptom checklist) given the low incidence of the
four cancers below that age covered in the campaign. Five Cancer
Council WA project officers, with a health promotion background,
and a combined full time equivalent of 3.0, delivered the Find
Cancer Early campaign across the three regions of WA in Trial
Area A. They used a community engagement approach building
local partnerships to deliver and disseminate the campaign
messages with face-to-face presentations, displays and distribution
of campaign materials. Paid advertising and promotional news
media items in regional newspapers and local radio supplemented
this dissemination strategy as these are known to have significant
local reach and account for variable levels of literacy. Television
was not used for news media or advertising to avoid contamination
in the control area.
The GP Intervention. A GP education resource card was created
which included the CAPER symptom RATs for colorectal
(Hamilton et al, 2005b), lung (Hamilton et al, 2005a) and prostate
(Hamilton et al, 2006) cancer. The resource card contained the
clinical implications of these risk tools including guidelines on
diagnostic assessment. (see Supplementary Material for example)
The resource card also summarised the National Breast and
Ovarian Cancer Centre guidelines for investigating new breast
symptoms(National Breast and Ovarian Cancer Centre, 2006) and
local referral guidelines and hospital contacts, including recom-
mendations about access to cancer multidisciplinary teams
(Department Of Health, WA, 2008). The GP resource card was
implemented through a series of four academic detailing practice
visits, supplemented by a series of case studies completed between
visits designed to reinforce key messages (Grimshaw et al, 2004).
Each practice visit discussed specific components of the resource
card and facilitated discussion within the practice about recently
diagnosed cancer patients. The educational visits were delivered by
the Cancer Council WA project officers. The GP intervention was
designed to reduce time to diagnosis by promoting earlier
recognition and investigation of suspicious symptoms by GPs
and clarifying cancer diagnostic pathways.
Outcomes. The primary outcome was the total diagnostic interval
(TDI), defined as the time from first symptom to cancer diagnosis.
We report our time intervals according to the principles outlined in
the ‘Aarhus Statement’ on the conduct and reporting of research
on cancer diagnosis,(Weller et al, 2012) and have used the Model
of Pathways to Treatment as our theoretical framework (Walter
et al, 2012, Scott et al, 2013). The date of first symptom was defined
as ‘the time-point when first bodily change(s) and/or symptom(s)
were noticed’ (up to two years before the date of diagnosis). For
screen-detected cases we used the date of attendance for the
screening test as the initial date in the patient pathway. Date of
diagnosis was based on date of pathological diagnosis as reported
to the WA Cancer Registry. Where data were available, we divided
the TDI into: time from first symptom to first presentation to
healthcare (Patient Interval); time from first healthcare presenta-
tion to first referral to specialist (First Healthcare Interval); and
time from referral to specialist until date of diagnosis (Specialist
Interval) (Weller et al, 2012). For patient-reported dates, where
uncertainty existed, we applied mid-point rules to estimate the
actual date (Allgar and Neal, 2005, Walter et al, 2015). Where
necessary, a clinical consensus group of three reviewed the data,
blinded to allocation, to confirm the date of first symptom and first
presentation to healthcare.
Measurement of primary outcome. The following instruments
were used to obtain information about symptoms and dates to
calculate the TDI:
1. SYMPTOM questionnaire. This self-administered questionnaire
was adapted from the C-SIM(Neal et al, 2014) measure and has
been applied in the UK SYMPTOM study (Walter et al, 2015,
2016). It includes items specific to each tumour site to capture
details of symptoms, their date of onset and time taken to seek
help. For each tumour type, the participant is asked an open
question about their first symptom, followed by a list of tumour-
specific symptoms.
2. GP record audit tool. This tumour-specific proforma captures
information on: the date, type and duration of presenting
symptoms within the last 12 months, referral information
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including referral date, and date of first appointment with
specialist.
Measurement of secondary outcomes
Process measures of intervention delivery. We collected data to
measure the symptom awareness campaign dose including media
exposure, distribution of resources and number of campaign
events. We measured uptake of GP education including GP
attendance at practice visits and completion of case studies. These
data were used to estimate the cost to deliver each intervention.
As per our trial protocol we will report at a later date analyses
from the WA linked datasets on the effects of interventions on
healthcare utilisation and clinical outcomes. This will include data
on cancer incidence, staging (or pseudo-staging where complete
staging data are unavailable) and mortality.
Statistical analysis. Our original minimum sample size calculation
before the trial commenced required 840 participants for 80% power
and a¼ 0.05 to detect a halving of the risk of long-delay from 30% to
15%. However, higher than expected accrual rates allowed us to
revise our power estimates on the basis of a clinically more
meaningful outcome, difference in the TDI. Accounting for the
design effects from hierarchical correlations and an intra-class
correlation coefficient of 0.09 based on similar trial designs,(Camp-
bell et al, 2004) our final sample size of 1359 participants provided
80% power to detect a 10% difference in TDI between intervention
groups for all four cancers combined, and a 20% difference in TDI
for breast, colorectal and prostate cancer separately, based on the
TDI distribution from our exploratory research (Emery et al,
2013a,b). We therefore report differences in TDI for all our analyses.
The primary analysis compared the TDIs and its sub-
components between trial groups. Given the skewed nature of
time data, we applied a log transformation prior to conducting
general linear modelling to compare intervals. Within the models
we accounted for: exposure to the community and GP interven-
tions and potential interactions relating to the factorial design,
practice size and clustering effects at the general practice level
using robust standard errors. Analyses were conducted as intention
to treat only. We conducted sensitivity analyses excluding ‘vague’
first symptoms such as fatigue and ‘feeling different’ and screen-
detected cases. Analyses were performed using Stata version 14.
RESULTS
From 1 March 2012 to 31 March 2014 2592 potentially eligible
participants were invited into the trial of whom 1358 (52.4%)
consented (Figure 1). The vast majority of these were recruited via
the WA Cancer Registry, only 71 (5.2%) through the CCWA
residential lodges. We could calculate a TDI for 1314 (96.8%)
participants at the level of the Community Intervention and for
1136 (83.7%) participants at the GP level. Table 1 presents the
baseline characteristics of the participants at the Community level
by tumour type showing balance in terms of age. Mean Socio-
Economic Indexes for Areas (SEIFA) scores on the Index of
Relative Socio-economic Advantage and Disadvantage (http://
www.abs.gov.au/websitedbs/censushome.nsf/home/seifa) were
similar (community intervention mean 977.8, mean rank 46.3;
community control mean 980.6, mean rank 47.1) suggesting
comparability in terms of a range of measures of income,
qualifications and occupations. The larger population of the
community control area meant an imbalance in total number of
cases diagnosed compared to the community intervention.
An estimated population of 121 600 aged over 40 years (the
target population) resided in the community intervention area.
During the Community Intervention there were: 130 388 symptom
checklists, 4170 DVDs and 74 317 symptom postcards distributed;
312 community presentations attended by 6549 people; 89 articles
in regional newspapers (reach: 573 380); 602 articles and/or
symptom checklists published in local newspapers (reach:
283 520); 10 local radio interviews; 162 paid newspaper advertise-
ments (reach 2 262 498) and 1490 30 s paid radio advertisements.
The campaign was widely distributed across all regions maximising
potential exposure to the whole target community. Sixty-nine
general practices were invited to receive the GP Intervention. Fifty-
six practices agreed to a single educational practice visit, 46 to two,
41 to three and 40 practices received all four visits.
The estimated cost of delivering the Community Intervention
was $878 687 and in addition we received in-kind support to the
level of $262 500. The estimated cost of delivering the GP
Intervention was $179 965 with additional in-kind support of
$125 250. Costs for teleconferencing, recruitment, and computing
($13 750) and in-kind office space ($105 000) were duplicated, so
totals have been adjusted to reflect the interventions running
independently of each other. Approximately 71% of campaign
costs were accounted for by salaries, and 18% towards paid
advertising. Approximately 75% of GP intervention costs were staff
salaries. Costs reflect 2012/13 AUD.
Table 2 presents the TDI by group randomisation and by factorial
level. The median TDIs by group randomisation were similar; after
log transformation there were no statistically significant differences in
the TDI at the Community or GP levels, or by factorial design:
Community intervention vs control: median TDI 107.5 vs 92 days; ln
mean difference 0.08 95% CI  0.06–0.23 P¼ 0.27; GP intervention
vs control: median TDI 97 vs 96.5 days; ln mean difference 0.004 95%
CI  0.18–0.19 P¼ 0.99. Table 3 presents the TDIs by group and
factorial design and tumour type. The median TDIs by group
randomisation were similar; after log transformation there were no
statistically significant differences in the TDI at the Community or
GP levels, or by factorial design for any tumour group (breast cancer:
Community intervention vs control: median TDI 33 vs 32 days; ln
mean difference 0.13 95% CI  0.13–0.39 P¼ 0.32 ; GP intervention
vs control: median TDI 34.5 vs 33 days; ln mean difference 0.12 95%
CI  0.20–0.43 P¼ 0.67; Colorectal cancer: community intervention
vs control: median TDI 107 vs 133 days; ln mean difference  0.26
95% CI  0.63–0.11 P¼ 0.16; GP intervention vs control: median
TDI 124 vs 122 days; ln mean difference  0.03 95% CI  0.51–0.45
P¼ 0.42; lung cancer: community intervention vs control: median
TDI 114.5 vs 114 days; ln mean difference 0.06 95% CI  0.39–0.51
P¼ 0.79; GP intervention vs control: 115 vs 125 days; ln mean
difference 0.02 95% CI  0.56–0.60 P¼ 0.45; prostate cancer:
community intervention vs control: 107.5 vs 92 days; ln mean
difference 0.16 95% CI  0.01–0.33 P¼ 0.06 GP intervention vs
control: 97 vs 96.5 days ln mean difference  0.05 95% CI  0.27–
0.17 P¼ 0.30).
Table 4a–c presents the Patient, First Healthcare and Specialist
Intervals by level of randomisation and tumour type. The median
patient intervals between those in Community Intervention and
Community Control regions were similar (44.5 vs 48.5 days), as were
the First Healthcare Intervals between GP intervention and GP
control groups (14 vs 15 days). After log transformation there were
no statistically significant differences in the Patient, First Healthcare
or Specialist Intervals by factorial design or tumour type (patient
interval community intervention vs control ln mean difference
 0.09 95% CI  0.36–0.18 P¼ 0.51; First Healthcare Interval ln
mean difference GP intervention vs control  0.27 95% CI  0.71–
0.18 P¼ 0.47; specialist interval ln mean difference Community
intervention vs control 0.06 95% CI  0.18–0.29 P¼ 0.65; GP
intervention vs control 0.17 95% CI  0.12–0.47 P¼ 0.49).
The protocol-driven sensitivity analyses excluding vague
symptoms as the first symptom and screen-detected cases did
not alter the main findings for the TDI or its sub-components. All
interactions were statistically not significant so were not considered
further.
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DISCUSSION
Summary findings. This is the first controlled trial worldwide to
test the separate and combined effects of community symptom
awareness campaign and GP educational interventions on time to
cancer diagnosis. In this large rigorously conducted trial over a 2-
year period of intervention, we found no evidence of an effect of
either intervention on time to cancer diagnosis. Furthermore, we
found no specific effect of the community intervention on the time
participants took to present with symptoms or of the GP
intervention on time from presentation to referral.
INCIDENT CASES
N = 2795
Fit diagnosis/region criteria
Trial region A = 1032  
Trial region B = 1763
INVITED
N = 2592 (93%)
Trial region A = 951  
Trial region B = 1641
NOT INVITED
N = 203
Reasons:
Died pre invite: 189
Other: no address (8); 
Name issue (3); other (1); 
Inappropriate timing (2)
COMMUNITY CONTROL
(TRIAL REGION B)
N = 832
INCOMPLETE DATA FOR TDI
N = 29
Reasons: missing info; poorly 
completed questionnaire or GP 
proforma, or unable to obtain
GP info.
INTERVENTION 
PRACTICES N = 30
PATIENTS N = 203
CONTROL
PRACTICES N =38
PATIENTS N =383
INTERVENTION 
PRACTICES N = 39
PATIENTS N = 345
CONTROL 
PRACTICES N =35
PATIENTS N = 205
ATTENDED GP FROM NON-
RANDOMISED PRACTICE*
N = 66
NO GP NOMINATED
N = 8
ATTENDED GP FROM NON-
RANDOMISED PRACTICE*
N = 94
NO GP NOMINATED
N =10
INCOMPLETE DATA FOR TDI
N = 15 
Reasons: missing info; poorly
completed questionnaire or GP
proforma, or unable to obtain
GP info.
RESPONDERS
N = 1358
Trial region A = 497 (37%)
Trial region B = 861 (63%)
DIED ≤ 30 days after 
invitation
N = 30
Non-responders / declined
N = 1204
Non responders: 819
Opted-out: 319
Return to sender: 51
Unusable data: 15
COMMUNITY CAMPAIGN
(TRIAL REGION A)
N = 482
Figure 1. Trial flow chart. *Non-randomised practice refers to practices from the trial areas which were unknown at time of randomisation, and
practices outside the trial regions.
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Strengths and limitations. There are several strengths to the
design of this trial: the interventions were carefully developed from
previous exploratory research conducted in rural Western
Australia, and were tailored to meet specific identified barriers to
timely cancer diagnosis. We rigorously applied the Aarhus
guidelines to the measurement and reporting of studies of
diagnostic intervals, underpinned by a theoretical model of
Pathways to Treatment (Walter et al, 2012, Weller et al, 2012,
Scott et al, 2013). Our measurement of the patient interval used a
well-established instrument designed to collect information about
duration of symptoms and dates of presentation to healthcare.
There are inevitable limitations in the accuracy of such self-
reported measures, such as recall bias and inaccurate recollection
of precise dates, but there is no known better way of obtaining data
on such intervals in cancer patients. Any measurement error is
likely to be equally distributed between trial groups and so should
not alter the trial comparisons.
We recruited over 50% of all incident cases who were eligible
for the trial, a very good response rate for recruitment through
a cancer registry. Although it is possible that we may have
been subject to survival bias, in that those with more advanced
disease were less likely to participate, this bias should not
have differentially affected the trial groups in relation to the
primary outcome. We chose to include screen-detected cases
because the interventions could potentially have contributed to
decisions to seek screening and GP referral pathways. Our
sensitivity analysis excluding screen-detected cases did not alter
our conclusions.
There are acknowledged weaknesses in our design: we had no
urban comparator groups which could have provided additional
useful comparative data on time to diagnosis. However, the
community intervention was designed specifically for a rural
Australian population making an urban comparison group of less
direct relevance. We conducted the trial in Western Australia due
Table 1. Trial participants’ baseline characteristics
Breast Colorectal Lung Prostate
Age SEIFA Age SEIFA Age SEIFA Age SEIFA
n Mean s.d. Median IQR Mean n Mean s.d. Median IQR Mean n Mean s.d. Median IQR Mean n Mean s.d. Median IQR Mean
Community intervention
Male 56 67.2 10.7 68.5 13.5 973.9 30 67.1 9.3 66 13.3 983.3 200 66.0 8.8 67 13 977.9
Female 144 58.7 11.8 59 16.3 977.1 47 65.7 13.4 68 18.5 979.8 20 62.0 8.7 61.5 12.3 984.6
Community control
Male 79 68.0 9.2 70 11 980.7 40 69.0 8.0 70 9.3 971.6 365 66.9 8.0 67 11 980.5
Female 277 60.9 11.9 62 18 981.2 73 66.8 10.6 67 14 982.6 27 67.4 9.4 69 12 980.1
Abbreviation: IQR ¼ interquartile range; SEIFA¼ Socio-Economic Indexes for Areas.
Table 2. Total diagnostic interval by trial group and by factorial design
n
Meana
Ln Mean Median 25th 75th
Trial group randomisation
CI 482 4.48 168.5 107.5 36 239.5
CC 832 4.40 151.5 92 35 207.5
GPI 548 4.43 154.7 97 35 213
GPC 588 4.42 160.7 96.5 34.3 215
Factorial level of randomisation
Community and GP interventions 203 4.40 157.6 100 36 228
Community control and GP intervention 345 4.42 153.0 92 34.5 204
Community intervention and GP control 205 4.46 176.4 103 33.5 241
Community and GP control 383 4.41 152.3 95 35 213
Abbreviations: CI¼ community intervention; CC¼ community control; GPC¼general practice control; GPI¼general practice intervention.
aNatural log of mean. All other values in days.
Table 3. Total diagnostic interval by trial group, factorial design and tumour type
Breast Colorectal Lung Prostate Total
Trial
group n
Mean
Lna Mean Med’n 25th 75th n
Mean
Lna Med’n 25th 75th n
Mean
Lna Med’n 25th 75th n
Mean
Lna Med’n 25th 75th n
Mean
Lna Med’n 25th 75th
CI 143 3.80 97.5 33 21 115 103 4.44 177.7 107 53 48 4.64 190.6 114.5 46.3 188 4.98 212.1 161.5 86 482 4.48 168.6 107.5 36
CC 275 3.67 82.5 34 18 97 146 4.70 195.3 133 53 65 4.58 157.4 114 53.5 346 4.82 186.8 123.5 66.8 832 4.40 151.5 92 35
GPI 176 3.77 83.0 34.5 19.3 100.8 118 4.54 185.3 124 43 55 4.66 180.7 115 55 199 4.88 192.9 139 74 548 4.43 154.7 97 35
GPC 196 3.69 91.8 33 18 91.5 94 4.57 185.3 122 57.3 45 4.64 170.4 125 49 253 4.93 203.1 148 76.5 588 4.42 160.7 96.5 34.25
CI and GPI 56 3.83 89.3 37 19.3 121 49 4.41 170.3 107 43 26 4.40 162.4 103.5 36.3 72 4.95 200.4 143 86.3 203 4.44 157.6 100 36
CC and
GPI
120 3.74 80.1 34 19.3 97.8 69 4.64 195.9 128 42.5 29 4.89 197.1 119 71.5 127 4.83 188.6 129 69 345 4.42 153.0 92 34.5
CI and
GPC
68 3.71 99.1 31 21.3 88.8 38 4.34 179.7 98 62 13 5.06 263.2 173 56.5 86 5.01 222.9 163.5 79.8 205 4.46 176.4 103 33.5
CC and
GPC
128 3.63 87.9 33.5 17.3 92 56 4.73 189.2 134 55.8 32 4.47 132.7 110.5 42.8 167 4.88 193.0 132 73 383 4.41 152.3 95 35
Abbreviations: CI¼ community intervention; CC¼ community control; GPC¼general practice control; GPI¼general practice intervention.
aNatural log of mean. All other values in days.
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to the isolated nature of many rural communities and because our
previous exploratory research identifying barriers to help-seeking
was based on patients from these regions. It would have been
logistically even more challenging and expensive to compare rural
regions in different States in Australia. Furthermore, conducting
such a trial between Australian States would introduce significant
confounding due to differences in healthcare systems. The selection
of trial regions for the Community Intervention was matched as
carefully as possible during the planning phase, within the
geographical limitations of a large and sparsely populated state.
However, there were only two community clusters in this trial,
limiting our ability to account fully for clustering at this level in our
analyses and raising the possibility of unbalanced confounders
across the two community trial groups. Differential population
Table 4a. Patient interval by trial group, by factorial design and tumour type
Breast Colorectal Lung Prostate Total
Trial
group n
Mean
Lna Mean Med’n 25th 75th
n
Mean
Lna Mean Med’n 25th 75th n
Mean
Lna Mean Med’n 25th 75th n
Mean
Lna Mean Med’n 25th 75th n
Mean
Lna Mean Med’n 25th 75th
CI 104 2.92 73.8 18.5 4 77.8 86 3.64 118.1 50.5 14 180 36 3.70 111.5 54.5 17.8 155.5 80 3.97 136.0 86.5 18.8 183.8 306 3.49 106.9 44.5 10 160
CC 165 3.17 80.6 29 5.5 99 114 3.64 113.5 53 14 148.8 57 3.26 83.6 30 7 103 132 4.18 146.8 91 28.3 202.5 468 3.58 107.7 48.5 12 142.25
GPI 117 3.18 77.3 29 6.5 98 94 3.48 99.4 34 11 102 47 3.47 106.4 36 8 151 76 4.31 146.3 103.5 36 183.5 334 3.56 103.1 45 10.5 134
GPC 124 3.10 84.8 21 5 95 75 3.70 119.5 77.5 14 161 37 2.96 79.0 39.5 8.3 101.8 104 4.12 155.5 93.5 24 213.5 340 3.58 113.4 54 13 147
CI and
GPI
40 3.04 85.5 21 3.3 106.8 38 3.71 108.1 54 15.5 209.3 22 3.59 107.5 54.5 16.8 152.5 31 4.05 122.0 78 21 177 131 3.568 104.4 54 12 160
CC
and
GPI
77 3.25 73.0 30 7.5 95.5 56 3.33 93.5 30 9 89 25 3.37 105.3 28 7.5 23.8 45 4.49 163.0 118 45 211.5 203 3.56 102.6 41 10 129
CI and
GPC
51 2.82 67.5 14 4 73 33 3.33 112.3 43 10.5 92 8 3.76 107.7 61 23.8 100.5 40 4.04 152.6 106 15.8 197 132 3.37 106.9 40 7 116.5
CC
and
GPC
73 3.30 96.5 26 5.5 119.3 42 3.99 125.12 106 22.5 179 29 3.30 71.1 34.5 7 103.5 64 4.18 157.3 91.5 27.3 288.3 208 3.71 117.6 64 14 160
Abbreviations: CI¼ community intervention; CC¼ community control; GPC¼general practice control; GPI¼general practice intervention.
aNatural log of mean. All other values in days.
Table 4b. First health encounter interval by trial group, by factorial design and tumour type
Breast Colorectal Lung Prostate Total
Trial
group n
Mean
Lna Mean Med’n 25th 75th n
Mean
Lna Mean Med’n 25th 75th n
Mean
Lna Mean Med’n 25th 75th n
Mean
Lna Mean Med’n 25th 75th n
Mean
Lna Mean Med’n 25th 75th
CI 129 1.94 32.3 14 6 24.5 78 0.21 36.2 2.5 0 33.3 30 3.24 70.53 47.5 11.3 79 163 2.20 46.0 15 7 36 400 1.724 41.49 14 5 32.75
CC 258 1.95 25 14.5 6 28 131 0.56 44.9 10 0 40 47 2.32 58.13 16 6 50 329 2.15 46.6 14 6 41.5 765 1.822 39.72 14 5 35
GPI 160 1.73 20.4 13 6 25.8 100 0.41 50.4 10 0 51 40 2.33 68.15 16.5 6.3 68.8 182 2.29 47.1 14 6 36.25 482 1.719 40.66 14 4 33.5
GPC 186 2.14 31.9 15 7 27.5 84 0.45 36.9 8 0 33 32 2.93 53.63 26 7 63 239 2.27 44.9 17 7 42 541 1.984 39.7 15 6 35
CI
and
GPI
47 1.37 17.0 13 3 24 35 0.38 49.6 12 0 51 19 2.85 72.89 14 6 103 61 2.52 56.9 15 7 46 162 1.765 45.63 14 4.75 35
CC
and
GPI
113 1.88 21.8 13 6 28.5 65 0.42 50.8 10 0 63.8 21 1.87 63.86 17 5 41 121 2.18 42.2 14 5 31 320 1.696 38.14 13 4 32
CI
and
GPC
65 2.36 42.1 14 8 24.5 32 0.20 32.8 7 0 33.8 8 3.99 66.88 55 47.3 68.3 78 2.26 38.8 15 7 36 183 2.011 40.15 14 7 31
CC
and
GPC
121 2.03 26.4 15.5 7 28 52 0.61 39.4 8 0 31 24 2.57 50.54 10.5 5.3 59.8 161 2.28 47.7 18 6.25 47.75 358 1.970 39.46 16 6 35
Abbreviations: CI¼ community intervention; CC¼ community control; GPI¼general practice intervention; GPC¼general practice control.
aNatural log of mean. All other values in days.
Table 4c. Specialist interval by trial group, by factorial design and tumour type
Breast Colorectal Lung Prostate Total
Trial
group n
Mean
Lna Mean Med’n 25th 75th n
Mean
Lna Mean Med’n 25th 75th n
Mean
Lna Mean Med’n 25th 75th n
Mean
Lna Mean Med’n 25th 75th n
Mean
Lna Mean Med’n 25th 75th
CI 86 1.91 20.0 13 5.8 23 77 3.40 54.1 36 14 71 27 2.53 40.6 16 21 72 165 4.36 114.2 83 165 228 355 3.42 72.6 39 15 91
CC 146 1.70 22.3 11.5 4 23.3 133 3.48 71.6 39 21 72 47 2.80 28.3 16 8 36 330 4.14 94.4 63 330 63 656 3.37 69.0 41 16 78.8
GPI 95 2.04 23.9 13 6 29 100 3.61 76.4 41 23 93 38 2.64 25.3 14.5 6.75 26.5 183 4.29 106.8 73 38 140 416 3.36 73.1 39 16 93
GPC 113 1.49 17.3 10 5 21.8 83 3.36 60.3 36 15.5 58.5 31 2.84 44.2 19 11 36 240 4.17 98.3 68 38 119 467 3.29 68.4 40.5 14 77
CI and
GPI
32 1.20 19.8 15.5 5 27.5 35 3.60 62.4 42 21 94 17 2.56 17.2 16 10 24 62 4.34 109.8 91 37.75 140.8 146 3.44 67.9 37.5 16 93.3
CC and
GPI
63 2.06 25.9 13 6 29 65 3.62 83.9 40 23 92.5 21 2.70 31.9 14 6 40.5 121 4.27 105.2 71 38 140.5 270 3.48 75.9 41 15.5 92
CI and
GPC
44 1.56 15.7 11 5.3 19.5 31 3.27 47.0 28 13 57 7 2.10 102 12 5 28 78 4.33 115.2 76.5 48 138.3 160 3.27 74.0 39 13.3 84
CC and
GPC
69 1.44 18.3 10 4 22 52 3.40 68.3 41 17 60 24 3.06 27.4 19 11.75 44.25 162 4.10 90.2 62 35 111 307 3.30 65.4 41 16 73.8
Abbreviations: CI¼ community intervention; CC¼ community control; GPI¼general practice intervention; GPC¼general practice control.
aNatural log of mean. All other values in days.
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growth in the community control regions during the trial meant a
larger proportion of participants were in the control arm, but this
did not impact our power to detect a small difference in the TDI.
In our Australian context, multiple cluster randomisation of
small local communities was not possible, because of our reliance
on regional radio and newspaper media outlets that covered large
swaths of the Community Intervention area, but which did not
overlap into the control area. Our design was thus necessitated by
the imperative to avoid campaign contamination to the control
area. We analysed the data on the basis of intention to treat. Not all
general practices participated in the intervention and we do not
know the precise extent to which individuals with cancer were
exposed to the community campaign. Intention to treat analyses
could potentially reduce our ability to identify an effect of the
interventions. Despite these accepted limitations, we question if an
improved experimental design using the same methods of
community intervention could be achieved anywhere else in the
world given the isolated nature of communities of rural Western
Australia. Thus, our design represents the best level of evidence
that is likely to be achieved in addressing the research question at
hand.
Given these pragmatic challenges of conducting trials of
community level interventions, how could potential imbalance
between confounders explain our null result? If the community
intervention was truly effective, baseline confounding would have
been such that, in the absence of intervention, Trial Area A
(community intervention) would have fared worse than the Trial
Area B (community control). Alternatively, the intervention might
have been harmful, causing greater delays, but baseline confound-
ing was such that Trial Area A would have fared better than Trial
Area B in the absence of intervention. We believe it is very unlikely
that an intervention of this nature could actually cause greater
delays in diagnosis. Thus the only credible alternative explanation
for the null trial result is the first of these two possibilities.
Whilst we have limited data on the case-mix of those diagnosed
with cancer during the trial, a wide range of socio-demographic,
health care delivery measures and cancer incidence were compared
between trial areas at baseline and found to have balanced
distributions. Importantly, SEIFA scores, measuring several
components of socio-economic disadvantage, were similar between
trial participants from community intervention and control
regions. Unfortunately we do not have pre-trial data on diagnostic
intervals but, if there had been a material imbalance of
independent determinants of diagnostic delay between the two
trial areas, one would expect cancer mortality rates to have been
worse in the Trial Area A before the trial. In fact this was not the
case; age-standardised mortality rates for the four cancers were:
Trial Area A male 56.3, female 43.9; Trial Area B male 57.1, female
46.3 per 100 000 person-years. If Trial Area A were destined to
have a worse outcome than the control area, and this was mitigated
by the intervention, one would expect to observe an unfavourable
difference in delay times affecting the earliest cancers diagnosed
during the trial, to then be balanced by a reversal of this for cancers
diagnosed towards the end of the study as the community
intervention took full effect. We examined this possibility but did
not report it as it was not in the original protocol. This never
occurred and the null result remained consistent across cancers
diagnosed early and late in the intervention period. In summary,
we believe that imbalance between confounders between the
community intervention and control regions is not the explanation
for our findings.
Context with existing literature. Why did we find no effect? It is
possible that the dose of the interventions was simply too small to
have a measureable influence on the primary outcome. The money
spent on the Community Intervention was relatively modest
compared to other national and international cancer awareness
and prevention campaigns with a small staff committed over a
large geographic area. The Community Intervention was based on
principles of community engagement. To avoid contamination we
did not use television and, although our process measures of reach
showed significant awareness and initial cognitive impact of key
components of the campaign,41 compared with other public health
campaigns, our total expenditure on the Find Cancer Early
campaign was relatively small. It was not feasible to obtain data
either from a wider population of people presenting with
symptoms associated with cancer or data on diagnostic intervals
preceding the trial. Our community telephone survey mid-way
through the campaign suggested differences between community
and control regions in symptom awareness and intentions to seek
help in favour of the intervention (Gray et al, 2015). Specifically,
those in campaign regions were significantly more likely to
recognise specific cancer symptoms (blood in stools and urine and
an unusual lump); of those aware of the campaign, one quarter said
they had visited their GP about a specific symptom (Gray et al,
2015). But these findings were not translated into differences in
diagnostic intervals among those diagnosed with cancer during the
follow-up period. Importantly, follow-up occurred during the two-
year period and only for a further 3 months after intervention
delivery. The intervention effects are likely to be cumulative over
time and, given the lag between symptom onset and cancer
diagnosis, our period of follow-up is likely to have been too short
to identify small effects.
There is limited evidence about the benefits of symptom
awareness campaigns despite their widespread use internationally
(Austoker et al, 2009). Recent data from the English ‘Be Clear on
Cancer Campaigns’ have suggested potentially useful short-term
effects including increased presentations to general practice and
earlier stage lung cancer, but these are based on comparisons with
historical control data (Ironmonger et al, 2015). There are socio-
demographic differences in symptom awareness and barriers to
symptomatic presentation, with more deprived populations citing
greater barriers (Niksic et al, 2015). Rural Australians may be a
‘hard to reach’ population who respond more stoically to
symptoms, experience greater barriers to help-seeking, and are
therefore less likely to respond to these types of campaign (Emery
et al, 2013a).
Our GP Intervention was based on evidence about effective
interventions to change health professional behaviour (O’Brien
et al, 2007) and tailored to implement the CAPER cancer RATs
and cancer diagnostic pathways. An observational study of
implementing the same cancer RATs in English general practice
showed an increase in referrals for suspected lung and colorectal
cancer (Hamilton et al, 2013). That study included a computer
mouse-mat and a paper flipchart to remind GPs about the RAT
and may therefore have been a more constant reminder than our
GP resource card. Furthermore, the English study was set in the
context of a much larger and sustained national effort to raise
awareness amongst GPs about early cancer diagnosis. Our model
of implementation was based on a series of academic detailing
visits to reinforce educational messages and seek GP reflection on
their use. The Cochrane review of trials of academic detailing visits
found small to moderate effects on changing professional
behaviours but with large unexplained variation between trials
(O’Brien et al, 2007). While 81% of all practices accepted at least
one educational visit, only 58% received all four. Nonetheless, 71%
of practices who participated in the intervention chose to receive
all four visits suggesting high levels of acceptability. This is very
good reach for a general practice intervention in such a large
geographical area but may have been a factor in why we found no
effect of the intervention.
Our interventions were aimed predominantly at reducing
patient and GP delays along the diagnostic pathway. During this
trial only one cancer diagnostic pathway was implemented in WA
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to reduce specialist delay, a one-stop prostate cancer clinic for rural
patients (McCombie et al, 2015). A regional cancer centre was
opened in mid-2011 in Bunbury (Community Control region)
aimed at providing treatment for rural patients closer to home. The
GP intervention included information about preferred specialist
diagnostic pathways, including those linked to multidisciplinary
teams, but these pathways were not designed specifically as ‘fast-
track’ cancer referral pathways. Our interventions were therefore
limited in the ability to reduce the specialist interval component of
the TDI. The Specialist Interval can be a major contributor to the
TDI, especially, for example, for uninsured patients with colorectal
or prostate cancer who rely on public hospital services for
diagnostic tests where they may be longer waiting times. There
are no comparable published Australian data on TDIs for the
cancers studied in this trial. The median durations in our trial
cohort for lung and colorectal cancer were considerably longer
than those reported in recent cohorts of these cancers from
England(Walter et al, 2015, 2016) and are likely to represent
clinically important delays (Neal et al, 2015).
This is the first such trial of community symptom awareness or
GP interventions to use time to cancer diagnosis as a primary
outcome (Austoker et al, 2009, Mansell et al, 2011b). Others have
monitored a range of health service process measures such as GP
visits and GP referrals, and some larger observational studies have
measured cancer incidence. Given the focus of such interventions is
to reduce diagnostic delay we believe that the TDI was the most
appropriate primary outcome. Based on our pre-trial data, the trial
was sufficiently powered to detect relatively small but potentially
clinically important differences in the TDI. This paper reports on the
primary outcome. By 2018 the WA linked data will be available for
the trial period, at which point we will report any effects on cancer
incidence, stage at diagnosis, healthcare utilisation and survival.
CONCLUSIONS AND RECOMMENDATIONS
In the United Kingdom, Denmark and other international
jurisdictions, there have been significant investments in commu-
nity cancer symptom awareness campaigns and GP interventions,
including those aimed at implementing cancer RATs, with a focus
on reducing cancer diagnostic delay (Hiom, 2015). While much
emphasis has been made on a growing body of observational data
about possible benefits, until now there have been no large-scale
pragmatic trials reported which have measured their effect on time
to diagnosis. Our trial in large geographically isolated regions of
Australia, with known later cancer presentation and higher stage at
diagnosis, failed to find an effect of either community or GP
interventions on time to cancer diagnosis. This is unlikely to be due
to contamination between groups or imbalance in confounders,
but may reflect insufficient campaign dose or insufficient length of
follow-up. Future trials of public awareness campaigns should
consider approaches to measuring longer term effects and consider
designs that allow for use of television and other media.
Nonetheless, our results may in fact show that, at least in this
setting, community campaigns and GP education initiatives may
not be effective and alternative strategies, possibly focused on fast
track specialist pathways and improved access to diagnostic tests,
may be more important in reducing diagnostic delay and
improving cancer outcomes (Moller et al, 2015).
ACKNOWLEDGEMENTS
We wish to thank the following for their contributions to this trial:
Find Cancer Early Project Officers (Lisa Barr, Pam Foulkes-Taylor,
Libby Foster, Karen Hansen, Amanda Harding, Kerryn Keating,
Tracey Price, Jo Woodall), Cancer Council WA staff and associated
staff, Cancer Council WA Lodges, participants, GPs and hospital
specialists, Cancer Research UK, AH Crawford Treatment Society,
Department of Health WA, WA Cancer and Palliative Care
Network, WA Country Health Service, National Health and
Medical Research Council, Cancer and Palliative Care Research
and Evaluation Unit, Val Lishman Health Research Foundation,
WA Cancer Registry Staff, WA Data Linkage Branch, Pat Booth,
Rhonda Coleman, Hooi Ee, Dickon Hayne, Laura Keith, Andrew
Kirke, Mike Mears, Leanne Monterosso, Violet Platt, Iain Steve
Pratt, David Preen, Babu Simon, Craig Sinclair, Hayley Staples,
Simon Towler, Clare Willix. The project was a partnership with
Cancer Council Western Australia, the WA Cancer and Palliative
Care Network, and the Department of Health Western Australia.
JDE is funded by an NHMRC Practitioner Fellowship. FMW is
funded by an NIHR Clinician Scientist award.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
AUTHOR CONTRIBUTIONS
JDE, CDJH, CS, KA, AN, FMW, MB conceptualised and designed
the study. All authors assisted with the development of the
protocol, study design and refinement of study materials. All
authors contributed to implementation of the protocol and
acquisition of data. MB was responsible for the randomisation
and statistical analyses. All authors have been involved in drafting
and critical evaluation of the manuscript. All authors have read and
approved the final version.
DISCLAIMER
The NHMRC had no role in the design of this study, the primary
interpretation of data or decision to submit results. CCWA
contributed to the design and provided substantial practical
assistance in the delivery of the intervention; two authors (TS
and EC) are CCWA staff. The funders had no role in data analysis
or interpretation, or decision to publish the results.
DATA SHARING
Anonymised patient level data are available at on request from the
corresponding author. Consent was not obtained for data sharing
but the presented data are anonymised and risk of identification is
low.
REFERENCES
Adamson J, Cockayne S, Puffer S, Torgerson DJ (2006) Review of randomised
trials using the post-randomised consent (Zelen’s) design. Contemp Clin
Trials 27: 305–319.
AIHW (2010) Cancer in Australia 2010: an overview. Australian Institute of
Health and Welfare: Canberra, Australia.
Allgar VL, Neal RD (2005) Delays in the diagnosis of six cancers: analysis of
data from the National Survey of NHS Patients: Cancer. Br J Cancer 92:
1959–1970.
Athey VL, Suckling RJ, Tod AM, Walters SJ, Rogers TK (2011) Early diagnosis
of lung cancer: evaluation of a community-based social marketing
intervention. Thorax 67(5): 412–417.
The Improving Rural Cancer Outcomes Trial BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2017.310 1467
Austoker J, Bankhead C, Forbes LJ, Atkins L, Martin F, Robb K, Wardle J,
Ramirez AJ (2009) Interventions to promote cancer awareness and early
presentation: systematic review. Br J Cancer 101(Suppl 2): S31–S39.
Baade PD, Dasgupta P, Aitken J, Turrell G (2011a) Geographic remoteness
and risk of advanced colorectal cancer at diagnosis in Queensland: a
multilevel study. Br J Cancer 105: 1039–1041.
Baade PD, Youlden DR, Coory MD, Gardiner RA, Chambers SK (2011b)
Urban-rural differences in prostate cancer outcomes in Australia: what has
changed? Med J Aust 194: 293–296.
Butler J, Foot C, Bomb M, Hiom S, Coleman M, Bryant H, Vedsted P, Hanson
J, Richards M (2013) The international cancer benchmarking partnership:
an international collaboration to inform cancer policy in Australia,
Canada, Denmark, Norway, Sweden and the United Kingdom. Health
Policy 112: 148–155.
Campbell MK, Thomson S, Ramsay CR, Maclennan GS, Grimshaw JM (2004)
Sample size calculator for cluster randomized trials. Comput Biol Med 34:
113–125.
Cancer Research UK (2010) National Awareness and Early Diagnosis
Initiative. Cancer Research UK: UK.
Coory MD, Baade PD (2005) Urban-rural differences in prostate cancer
mortality, radical prostatectomy and prostate-specific antigen testing in
Australia. Med J Aust 182: 112–115.
Coory MD, Ho T, Jordan SJ (2013) Australia is continuing to make progress
against cancer, but the regional and remote disadvantage remains. Med J
Aust 199: 605–608.
Department of Health, WA. Model of Care for Cancer. Cancer & Palliative
Care Network, Department of Health: Perth, WA, Australia, 2008.
Department of Health and Ageing (2010) Delivering Regional Cancer Centres.
Canberra, Australia.
Emery JD, Gray V, Walter FM, Cheetham S, Croager EJ, Slevin T, Saunders C,
Threlfall T, Auret K, Nowak AK, Geelhoed E, Bulsara M, Holman CD
(2014) The Improving Rural Cancer Outcomes (IRCO) Trial: a factorial
cluster-randomised controlled trial of a complex intervention to reduce
time to diagnosis in rural patients with cancer in Western Australia: a
study protocol. BMJ Open 4: e006156.
Emery JD, Walter FM, Gray V, Sinclair C, Howting D, Bulsara M, Bulsara C,
Webster A, Auret K, Saunders C, Nowak A, Holman CD (2013a)
Diagnosing cancer in the bush: a mixed-methods study of symptom
appraisal and help-seeking behaviour in people with cancer from rural
Western Australia. Fam Pract 30: 294–301.
Emery JD, Walter FM, Gray V, Sinclair C, Howting D, Bulsara M, Bulsara C,
Webster A, Auret K, Saunders C, Nowak A, Holman D (2013b) Diagnosing
cancer in the bush: a mixed methods study of GP and specialist diagnostic
intervals in rural Western Australia. Fam Pract 30(5): 541–550.
Forbes LJ, Simon AE, Warburton F, Boniface D, Brain KE, Dessaix A,
Donnelly C, Haynes K, Hvidberg L, Lagerlund M, Lockwood G, Tishelman
C, Vedsted P, Vigmostad MN, Ramirez AJ, Wardle J. International Cancer
Benchmarking Partnership Module 2 Working, G (2013) Differences in
cancer awareness and beliefs between Australia, Canada, Denmark,
Norway, Sweden and the UK (the International Cancer Benchmarking
Partnership): do they contribute to differences in cancer survival? Br J
Cancer 108: 292–300.
Gray V, Croager E, Emery J, Slevin T, Pratt I, Holman D. Officers, F. C. E. P.
(2015) Development and Evaluation of the Find Cancer Early community
education campaign in regional Western Australia to reduce help-seeking
interval. Eur J Cancer Care 24: 16–16.
Grimshaw JM, Thomas RE, Maclennan G, Fraser C, Ramsay CR, Vale L,
Whitty P, Eccles MP, Matowe L, Shirran L, Wensing M, Dijkstra R,
Donaldson C (2004) Effectiveness and efficiency of guideline
dissemination and implementation strategies. Health Technol Assess 8:
iii-iv, 1–72.
Hall SE, Holman CD, Wisniewski ZS, Semmens J (2005) Prostate cancer:
socio-economic, geographical and private-health insurance effects on care
and survival. BJU Int 95: 51–58.
Hamilton W (2009) The CAPER studies: five case-control studies aimed at
identifying and quantifying the risk of cancer in symptomatic primary care
patients. Br J Cancer 101: S80–S86.
Hamilton W, Green T, Martins T, Elliott K, Rubin G, Macleod U (2013)
Evaluation of risk assessment tools for suspected cancer in general
practice: a cohort study. Br J Gen Pract 63: e30–e36.
Hamilton W, Peters TJ, Round A, Sharp D (2005a) What are the clinical
features of lung cancer before the diagnosis is made? A population based
case-control study. Thorax 60: 1059–1065.
Hamilton W, Round A, Sharp D, Peters TJ (2005b) Clinical features of
colorectal cancer before diagnosis: a population-based case-control study.
Br J Cancer 93: 399–405.
Hamilton W, Sharp DJ, Peters TJ, Round AP (2006) Clinical features of
prostate cancer before diagnosis: a population-based, case-control study.
Br J Gen Pract 56: 756–762.
Hiom SC (2015) Diagnosing cancer earlier: reviewing the evidence for
improving cancer survival. Br J Cancer 112(Suppl 1): S1–S5.
Hippisley-Cox J, Coupland C (2013a) Symptoms and risk factors to identify
men with suspected cancer in primary care: derivation and validation of
an algorithm. Br J Gen Pract 63: e1–10.
Hippisley-Cox J, Coupland C (2013b) Symptoms and risk factors to identify
women with suspected cancer in primary care: derivation and validation of
an algorithm. Br J Gen Pract 63: e11–e21.
Ironmonger L, Ohuma E, Ormiston-Smith N, Gildea C, Thomson CS, Peake
MD (2015) An evaluation of the impact of large-scale interventions
to raise public awareness of a lung cancer symptom. Br J Cancer 112
207–216.
Jong KE, Vale PJ, Armstrong BK (2005) Rural inequalities in cancer care and
outcome. Med J Aust 182: 13–14.
Mansell G, Shapley M, Jordan JL, Jordan K (2011a) Interventions to reduce
primary care delay in cancer referral: a systematic review. Br J Gen Pract
61: e821–e835.
Mansell G, Shapley M, Jordan JL, Jordan K (2011b) Interventions to reduce
primary care delay in cancer referral: a systematic review. Br J Gen Pract
61: e821–e835.
McCombie SP, Hawks C, Emery JD, Hayne D (2015) A ’One Stop’ prostate
clinic for rural and remote men: a report on the first 200 patients. BJU Int
116(Suppl 3): 11–17.
Meilleur A, Subramanian SV, Plascak JJ, Fisher JL, Paskett ED, Lamont EB
(2013) Rural residence and cancer outcomes in the United States:
issues and challenges. Cancer Epidemiol Biomarkers Prev 22:
1657–1667.
Mitchell KJ, Fritschi L, Reid A, Mcevoy SP, Ingram DM, Jamrozik K,
Clayforth C, Byrne MJ (2006) Rural-urban differences in the presentation,
management and survival of breast cancer in Western Australia. Breast 15:
769–776.
Moller H, Gildea C, Meechan D, Rubin G, Round T, Vedsted P (2015) Use of
the English urgent referral pathway for suspected cancer and mortality in
patients with cancer: cohort study. BMJ 351: h5102.
Moore HJ, Nixon C, Tariq A, Emery J, Hamilton W, Hoare Z, Kershenbaum
A, Neal RD, Ukoumunne OC, Usher-Smith J, Walter FM, WHYTE S,
RUBIN G (2016) Evaluating a computer aid for assessing stomach
symptoms (ECASS): study protocol for a randomised controlled trial.
Trials 17: 184.
National Breast And Ovarian Cancer Centre (2006) The Investigation of a New
Breast Symptom: A Guide for General Practitioners. National Breast and
Ovarian Cancer Centre: Australia.
Neal RD, Nafees S, Pasterfield D, Hood K, Hendry M, Gollins S, Makin M,
Stuart N, Turner J, Carter B, Wilkinson C, Williams N, Robling M
(2014) Patient-reported measurement of time to diagnosis in cancer:
development of the Cancer Symptom Interval Measure (C-SIM) and
randomised controlled trial of method of delivery. BMC Health Serv Res
14: 3.
Neal RD, Tharmanathan P, France B, Din NU, Cotton S, Fallon-Ferguson J,
Hamilton W, Hendry A, Hendry M, Lewis R, Macleod U, Mitchell ED,
Pickett M, Rai T, Shaw K, Stuart N, Torring ML, Wilkinson C, Williams B,
Williams N, Emery J (2015) Is increased time to diagnosis and treatment
in symptomatic cancer associated with poorer outcomes? Systematic
review. Br J Cancer 112(Suppl): S92–S107.
Niksic M, Rachet B, Warburton FG, Wardle J, Ramirez AJ, Forbes LJ (2015)
Cancer symptom awareness and barriers to symptomatic presentation in
England–are we clear on cancer? Br J Cancer 113: 533–542.
O’Brien MA, Rogers S, Jamtvedt G, Oxman AD, Odgaard-Jensen J,
Kristoffersen DT, Forsetlund L, Bainbridge D, Freemantle N, Davis DA,
Haynes RB, Harvey EL (2007) Educational outreach visits: effects on
professional practice and health care outcomes. Cochrane Database Syst
Rev. CD000409.
Scott SE, Walter FM, Webster A, Sutton S, Emery J (2013) The model of
pathways to treatment: conceptualization and integration with existing
theory. Br J Health Psychol 18: 45–65.
Singh GK, Williams SD, Siahpush M, Mulhollen A (2011) Socioeconomic,
rural-urban, and racial inequalities in US cancer mortality: part i-all
BRITISH JOURNAL OF CANCER The Improving Rural Cancer Outcomes Trial
1468 www.bjcancer.com |DOI:10.1038/bjc.2017.310
cancers and lung cancer and part ii-colorectal, prostate, breast, and
cervical cancers. J Cancer Epidemiol 2011: 107497.
Underhill CR, Goldstein D, Grogan PB (2006) Inequity in rural cancer
survival in Australia is not an insurmountable problem. Med J Aust 185:
479–480.
WA Country Health Service (2011) Regional Profiles. WA Country Health
Service, Department of Health: Perth, WA, Australia. Available at : http://
www.wacountry.health.wa.gov.au/index.php?id=506.
Walter F, Webster A, Scott S, Emery J (2012) The andersen model of total
patient delay: a systematic review of its application in cancer diagnosis. J
Health Serv Res Policy 17: 110–118.
Walter FM, Emery JD, Mendonca S, Hall N, Morris HC, Mills K, Dobson C,
Bankhead C, Johnson M, Abel GA, Rutter MD, Hamilton W, Rubin GP
(2016) Symptoms and patient factors associated with longer time to
diagnosis for colorectal cancer: results from a prospective cohort study. Br
J Cancer 115: 533–541.
Walter FM, Rubin G, Bankhead C, Morris HC, Hall N, Mills K, DOBSON C,
Rintoul RC, Hamilton W, Emery J (2015) Symptoms and other factors
associated with time to diagnosis and stage of lung cancer: a prospective
cohort study. Br J Cancer 112: S6–S13.
Weller D, Vedsted P, Rubin G, Walter FM, Emery J, Scott S, Campbell C,
Andersen RS, Hamilton W, Olesen F, Rose P, Nafees S, Van Rijswijk E,
Hiom S, Muth C, Beyer M, Neal RD (2012) The Aarhus statement:
improving design and reporting of studies on early cancer diagnosis. Br J
Cancer 106: 1262–1267.
This work is licensed under the Creative Commons
Attribution-Non-Commercial-Share Alike 4.0 Inter-
national License. To view a copy of this license, visit http://
creativecommons.org/licenses/by-nc-sa/4.0/
r The Author(s) named above 2017
1Department of General Practice and The Centre for Cancer Research, The University of Melbourne, Melbourne, VIC, Australia;
2School of Primary, Aboriginal and Rural Health Care, The University of Western Australia, Crawley, WA, Australia; 3The Primary
Care Unit, Department of Public Health & Primary Care, University of Cambridge, Cambridge, UK; 4School of Population Health,
The University of Western Australia, Crawley, WA, Australia; 5Education and Research Division, Cancer Council Western Australia,
Subiaco, WA, Australia; 6General Practice and Primary Health Care Academic Centre, Melbourne Medical School, The University
of Melbourne, Melbourne, VIC, Australia; 7School of Nursing, Midwifery and Paramedicine, Curtin University, Bentley, WA,
Australia; 8Education & Research Division, Cancer Council Western Australia; School of Psychology and Speech Pathology, Curtin
University, Bentley, WA, Australia; 9School of Surgery, The University of Western Australia, Crawley, WA, Australia; 10Western
Australia Cancer Registry, The Department of Health of Western Australia, Perth, WA, Australia; 11Rural Clinical School of Western
Australia, The University of Western Australia, Albany, WA, Australia; 12School of Medicine, The University of Western Australia,
Crawley, WA, Australia; 13Department of Medical Oncology, Sir Charles Gairdner Hospital, Perth, WA, Australia and 14Institute for
Health Research, University of Notre Dame, Freemantle, WA, Australia
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)
The Improving Rural Cancer Outcomes Trial BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2017.310 1469
